Comments*

 
  • Translational Research & Medicine

  • Events 

    Friday, May 24, 2013 | 8:30 AM - 4:30 PM

    Targeting Epigenetic Regulators for Cancer Therapy

    Speakers: Scott A. Armstrong (Memorial Sloan-Kettering Cancer Center), Stephen Baylin (The Johns Hopkins University School of Medicine), Robert A. Copeland (Epizyme, Inc.), Vicki L. Goodman (GlaxoSmithKline), Haitao Li (Tsinghua University, China), X. Shirley Liu (Dana-Farber Cancer Institute), Robert Sims (Constellation Pharmaceuticals, Inc.), Alexander Tarakhovsky (The Rockefeller University)

    Epigenetic research has shown that heritable changes in cancer cell transformation occur beyond the primary DNA sequence. This symposium reviews epigenetic regulators in cancer development and progress in designing therapies targeting the epigenome.

    Wednesday, June 5, 2013 | 12:00 PM - 4:00 PM

    Chemical Biology Discussion Group Year-End Symposium

    Keynote Speaker: Alanna Schepartz (Yale University)

    The Chemical Biology Discussion Group brings together chemists and biologists interested in discussing the latest breakthroughs. The year-end meeting features keynote speaker Alana Schepartz of Yale University and a poster session.

    Thursday, June 6, 2013 | 8:30 AM - 6:30 PM

    Capacity Building in Nutrition Science: Revisiting the Curricula for Medical Professionals

    Organizers: Sharon Akabas (Columbia University), Gerald Friedman (The Mount Sinai Hospital), Martin Kohlmeier (University of North Carolina), Charlotte Pratt (National Institute of Health), Gwen Twillman (American Society for Nutrition), Mandana Arabi (The Sackler Institute for Nutrition Science), Brooke Grindlinger (The New York Academy of Sciences)

    This conference aims to revisit the current nutrition curricula for health professionals and to explore how trainings can better provide the skills necessary for implementing the array of preventative and therapeutic nutrition interventions available. Presented as part of the Translational Medicine Initiative.

    June 19 - 20, 2013

    Progressive Multifocal Leukoencephalopathy

    Conference Planning Committee: Claudio Carini (Pfizer Inc.), Teresa Compton (Biogen Idec (Conference Chair)), Marion Kasaian (Pfizer Inc.), Theodora Salcedo (Bristol-Myers Squibb Company), Anne Vogt (F. Hoffmann-La Roche Ltd)
    Scientific Advisory Board: Leonard Calabrese (Cleveland Clinic), Paola Cinque (Hospital San Raffaele), David Clifford (Washington University School of Medicine), Robert Garcea (University of Colorado at Boulder), Eugene Major (National Institute of Neurological Disorders and Stroke), Kenneth Tyler (University of Colorado Anschutz Medical Campus), Thomas Weber (University of Hamburg)

    New basic science and clinical findings relevant to the pathogenesis, mitigation, cure, and risk stratification of Progressive Multifocal Leukoencephalopathy will support a discussion of current challenges and future directions for PML treatment.

    Monday, June 24, 2013 | 10:30 AM - 3:00 PM

    Translating Immunology Discoveries into Therapies: Inaugural Ross Prize in Molecular Medicine

    Speakers: Yasmine Belkaid (Mucosal Immunology Section, LPD), Dan R. Littman (New York University School of Medicine), Alexander Rudensky (Sloan-Kettering Institute)

    The Ross Prize, established in conjunction with the Feinstein Institute for Medical Research and Molecular Medicine, is awarded to an investigator producing innovative, paradigm-shifting research worthy of significant attention in molecular medicine.

  • Past Events

    Friday, May 17, 2013 | 8:00 AM - 4:30 PM

    The Three Zeros of Eliminating HIV / AIDS: Global Science and Policy

    Speakers: Myron S. Cohen (UNC School of Medicine), Chris Collins (amfAR, The Foundation for AIDS Research), Michele R. Decker (Johns Hopkins Bloomberg School of Public Health), Tim Horn (Treatment Action Group), Rick King (IAVI), Luiz Loures (UNAIDS), Mary A. Marovich (NIAID), Nelson L. Michael (Walter Reed Army Institute of Research), Julio Montaner (BC Centre for Excellence in HIV / AIDS), John P. Moore (Weill Cornell Medical College), Robert R. Redfield (University of Maryland School of Medicine), Bill Snow (Global HIV Vaccine Enterprise), Magdalena Sobieszczyk (Columbia University Medical Center), Annie Sparrow (Mount Sinai Global Health), Daniel Tietz (ACRIA), Mitchell Warren (AVAC), Jane Waterman (IAVI)

    The UNAIDS "three zeros" strategy provides a clear vision for future HIV / AIDS research and policy. This symposium tackles communication and collaboration, capacity-building for HIV prevention, care, and treatment, vaccine trials and a case study.

    Monday, May 6, 2013 | 8:15 AM - 4:00 PM

    Translating Natural Products into Drugs for Alzheimer's and Neurodegenerative Disease

    Speakers: Kurt R. Brunden (University of Pennsylvania), Grant J. Carr (AMRI), Gabriela Chiosis (Memorial Sloan-Kettering Cancer Center), Jerold Chun (The Scripps Research Institute), Bonnie M. Davis (Synaptec), Chad Dickey (University of South Florida), Frank E. Koehn (Pfizer Global R&D), David J. Newman (National Cancer Institute, NIH), Salvatore Oddo (University of Texas Health Science Center, San Antonio), Giulio Maria Pasinetti (Mount Sinai School of Medicine)

    Alzheimer's disease may benefit from the novel chemistries found in natural products. This conference explores drug discovery from natural products, including novel approaches and technologies, and promising Alzheimer's drug discovery programs.

    Tuesday, April 23, 2013 | 12:00 PM - 4:00 PM

    Targeting Insulin Resistance for the Treatment of Alzheimer's Disease: From Laboratory to the Clinic

    Speakers: Suzanne M. de la Monte (Brown University), William H. Frey II (Alzheimer's Research Center, Regions Hospital, St. Paul, MN), José A. Luchsinger (Columbia University Medical Center), Mark P. Mattson (National Institute on Aging, NIH), Ewan C. McNay (University at Albany, SUNY), Konrad Talbot (University of Pennsylvania)
    Organizers: Mercedes Beyna (Pfizer Global Research and Development), Cathleen Gonzales (Pfizer Global Research and Development), Barbara Petrack (Drew University), Jennifer Henry (The New York Academy of Sciences)

    Insulin resistance and dysregulated insulin signaling are observed in brains of Alzheimer's patients. Current diabetes drugs that improve cognition and brain insulin signaling in rodents are in clinical trials for mild cognitive impairment and AD.

    Monday, March 25, 2013 | 12:00 PM - 4:00 PM

    Treatment-Resistant Depression: Glutamate, Stress-Hormones and their Role in the Regeneration of Neurons

    Organizers: Robert Martone (Covance Biomarker Center of Excellence), Harald Murck (Covance Neuroscience Medical and Scientific Services), Jennifer Henry (The New York Academy of Sciences)
    Speakers: Ron Duman (Yale University), Guosong Liu (Tsinghua University, China), Jorge Quiroz (Roche), Simone Sartori (University of Innsbruck, Austria), Carlos Zarate (National Institute of Mental Health, NIH)

    Major depression is a devastating illness; current therapies based upon monoamine neurotransmitters are beneficial for only one in ten patients. This program reviews a paradigm shift in treatment targeting the glutamatergic neurotransmitter system.

  • Publications 

    Annals

    The Year in Immunology: Basic and Clinical Research in Human Immunology

    Edited by Noel R. Rose (The Johns Hopkins University, Baltimore, Maryland)

    The fifth installment of The Year in Immunology series focuses on research in human immunology.

    Volume 1285

    eBriefing

    Health 2.0: Digital Technology in Clinical Care

    Organizers: Johanne Morne (New York State Department of Health AIDS Institute), Sonja Noring (New York State Department of Health AIDS Institute), Cheryl Smith (New York State Department of Health AIDS Institute), AIDS Institute Social Media Workgroup (New York State Department of Health AIDS Institute), Brooke Grindlinger (The New York Academy of Sciences), and Kerstin Hofmeyer (The New York Academy of Sciences)

    This eBriefing looks at the impact of digital technologies on clinical care, especially for HIV and other sexually transmitted infections, exploring eHealth strategies for patient-centered care and clinical decision support.

    Annals

    The Renaissance of Cancer Immunotherapy: The 7th International Cancer Vaccine Symposium

    Edited by Olivera J. Finn (University of Pittsburgh, Pittsburgh, Pennsylvania) and Gerold Schuler (University Hospital of Erlangen, Erlangen, Germany)

    This Annals volume presents papers that discuss progress of immunology research toward the development of cancer vaccines.

    Annals

    Translational Immunology in Asia-Oceania: The 5th FIMSA Congress

    Edited by Narinder K. Mehra (All India Institute of Medical Sciences, New Delhi, India)

    This Annals volume presents papers from the fifth congress of the Federation of Immunological Societies of Asia-Oceania.

    Volume 1283

  • Webinar Archives

    Webinar Archive
    October 27, 2009

    Is Alzheimer's Disease Type 3 Diabetes?

    What is the connection between dysregulated neuronal insulin signaling and Alzheimer's disease? In a recent Academy webinar, some researchers argued that the neurodegenerative disease should be considered a type of diabetes.

  • Translational Medicine Initiative

    Macy FoundationThe Translational Medicine Initiative represents a three-year partnership between the New York Academy of Sciences and the Josiah Macy, Jr. Foundation to support the translation of basic science research into clinical applications.

    Learn more at www.nyas.org/TransMed.